LUND, Sweden, November 19, 2026
Asgard Therapeutics, a biotechnology company developing next-generation cancer immunotherapies, has secured a €2.5 million European Innovation Council (EIC) Accelerator grant to advance its lead program, AT-108, toward clinical development. The funding will support preparations for the company’s first-in-class in vivo direct cell reprogramming immunotherapy, with the goal of entering clinical development in 2027. The grant marks a significant milestone in Asgard’s efforts to translate its innovative cancer immunotherapy platform into clinical applications.
EIC Accelerator Funding Supports Clinical Development
Asgard Therapeutics was selected among 35 companies awarded grants in the latest European Innovation Council evaluation round, which attracted 453 proposals. The EIC Accelerator program supports innovative European startups and small and medium-sized enterprises developing breakthrough technologies with high commercial potential. The €2.5 million grant will help Asgard complete key preparatory activities required to move AT-108 into clinical development, supporting its planned transition toward a clinical-stage biotechnology company in 2027. In addition to the grant, the company is eligible for potential equity investment of up to €10 million from the EIC Fund, which could be pursued as part of an upcoming financing round. This additional investment opportunity could strengthen Asgard’s financial resources as it progresses its therapeutic program and prepares for clinical testing.
AT-108 Reprograms Tumor Cells Into Immune-Activating Cells
AT-108 is an off-the-shelf gene therapy designed to transform tumor-resident cells in vivo into cDC1-like antigen-presenting cells, a specialized cell population involved in activating cancer-fighting immune responses. The investigational therapy uses a replication-deficient adenoviral vector to deliver three proprietary reprogramming factors directly into tumor cells, modifying their gene-expression programs and converting them into dendritic-like cells capable of presenting tumor antigens. This approach is intended to trigger a personalized anti-tumor immune response without requiring the development of a patient-specific cell product outside the body. Asgard is initially targeting recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), microsatellite-stable colorectal cancer, and neoadjuvant treatment of locally advanced, resectable HNSCC. By converting tumor cells into immune-activating cells, AT-108 aims to address limitations associated with tumors that are poorly responsive to existing immunotherapies.
Preclinical Evidence Strengthens AT-108 Development
The grant announcement follows encouraging scientific progress supporting the AT-108 program. Earlier preclinical findings presented at the ASGCT Annual Meeting in May 2026 demonstrated that AT-108 monotherapy doubled median survival in checkpoint-refractory animal models, while combination treatment with immune checkpoint blockade significantly extended survival and achieved complete tumor regressions. More recently, Asgard published research in Immunity demonstrating the induction of cancer-fighting tertiary lymphoid structures across both cold and hot tumor types, further supporting the potential of its direct cell reprogramming platform. New data presented at SITC 2026 also established a translational biomarker framework for AT-108, potentially supporting future clinical evaluation, patient selection, and treatment-response monitoring. Together, these findings provide a growing preclinical and translational foundation as the company prepares for clinical development.
Source: Asgard Therapeutics press release



